Trinity Delta view: The pivotal G306 Grass MATA MPL Phase III trial is one of two important clinical studies planned, with the other the Phase I PROTECT VLP Peanut trial. Data for both of these key pipeline assets are expected next year, with results from G306 during Q423. The G306 study is fully funded, and should generate reliable and robust results given the size and scope. Management sees $300-400m peak sales for Grass MATA MPL in the US, which could be transformational for Allergy Therapeutics. Our Allergy Therapeutics valuation is £260.8m (38.4p per share) which includes a pipeline valuation of £190.0m (28.0p/share), where we see material upside potential as key programmes, including VLP Peanut and Grass MATA MPL, progress. Following the manufacturing pause, management remains focused on cost control and capital management and is assessing and reviewing all funding options.
08 Dec 2022
Trinity Delta Lighthouse: Allergy Therapeutics
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Trinity Delta Lighthouse: Allergy Therapeutics
- Published:
08 Dec 2022 -
Author:
Franc Gregori | Lala Gregorek | Philippa Gardner -
Pages:
2
Trinity Delta view: The pivotal G306 Grass MATA MPL Phase III trial is one of two important clinical studies planned, with the other the Phase I PROTECT VLP Peanut trial. Data for both of these key pipeline assets are expected next year, with results from G306 during Q423. The G306 study is fully funded, and should generate reliable and robust results given the size and scope. Management sees $300-400m peak sales for Grass MATA MPL in the US, which could be transformational for Allergy Therapeutics. Our Allergy Therapeutics valuation is £260.8m (38.4p per share) which includes a pipeline valuation of £190.0m (28.0p/share), where we see material upside potential as key programmes, including VLP Peanut and Grass MATA MPL, progress. Following the manufacturing pause, management remains focused on cost control and capital management and is assessing and reviewing all funding options.